J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
GSK on Role of AI, Technology in R&D: Vanguards of Health Care
"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...
Asia Pharmaceutical Regulatory Affairs Training Course: Practical Overview Of The Key Areas With Focus On India (ONLINE EVENT: February 25-27, 2025)
( MENAFN - GlobeNewsWire - Nasdaq) Dublin, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The "Pharmaceutical Regulatory Affairs in Asia Training Course" has been added to ResearchAndMarkets.com's offering.